Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.21.1
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Nov. 16, 2020
Feb. 28, 2009
Nov. 30, 2006
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Licensing and other arrangements            
Revenue from contracts with customers       $ 19 $ 500  
Takeda | Collaboration agreement            
Licensing and other arrangements            
Revenue from contracts with customers $ 2,000     0 $ 0  
Contract assets       0   $ 0
Capitalized contract costs       $ 0   $ 0
Takeda | Collaboration agreement | TAK-079            
Licensing and other arrangements            
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones     $ 19,000      
Royalty payment period from the first commercial sale of each royalty-bearing discovery product     13 years 6 months      
Royalty payment period from first commercial sale if there is significant generic competition post patent-expiration     12 years      
Takeda | Collaboration agreement | Other antibodies            
Licensing and other arrangements            
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,300        
Royalty payment period   10 years